Biohaven stock sinks on three-month delay for neuro drug's FDA approval decision

Biohaven said late Wednesday that the FDA would be delaying the PDUFA date for its neurodegenerative disease therapy troriluzole and will also require an advisory committee meeting to review the drug. The agency’s move came ...